Drug Metabolism and Pharmacokinetics最新文献_第10页

Physiologically based pharmacokinetic modeling of adeno-associated viruses and the transgene product 腺相关病毒和转基因产物的生理学药代动力学建模

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-05-13 DOI: 10.1016/j.dmpk.2023.100974

Shufang Liu, Ekram Chowdhury, Guy Meno-Tetang, Dhaval Shah

引用次数: 0

Utilization of target engagement in tissues measured by immunoaffinity LC-MS/MS for PBPK modeling of monoclonal antibody 利用免疫亲和力 LC-MS/MS 测定的组织中的目标参与度建立单克隆抗体的 PBPK 模型

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-05-13 DOI: 10.1016/j.dmpk.2023.100972

Yutaro Hoshi, Yuki Oda, Junji Komaba, Yoshiyuki Yamaura

引用次数: 0

Investigating cross-species differences of MDR1-mediated drug transport 调查 MDR1 介导的药物转运的跨物种差异

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-05-13 DOI: 10.1016/j.dmpk.2023.100983

Csilla Temesszentandrasi-Ambrus, Krisztina Heredi-Szabo, Emoke Soskuti, Nora Szilvasy, Emese Kis, Zsuzsanna Gaborik

引用次数: 0

Synthesis and characterization of human metabolites of the echinocandid drug rezafungin by microbial biotransformation 通过微生物生物转化合成棘白类药物雷沙芬净的人体代谢物并确定其特征

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-05-13 DOI: 10.1016/j.dmpk.2023.100942

Julia Shanu-Wilson, Ravi Manohar, Adriana Gomez, Richard Phipps, Jonathan Steele, Stephen Wrigley, Liam Evans, Frank Scheffler

引用次数: 0

Challenges in PBPK modeling of phenolic drugs extensively metabolized by intestinal phase II enzyme 酚类药物经肠道二期酶广泛代谢的 PBPK 建模难题

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-05-13 DOI: 10.1016/j.dmpk.2023.100977

Rashim Singh, Ming Hu, Lu Wang, Yifan Tu

引用次数: 0

Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials 用定量系统药理学洞察药物开发：利用虚拟临床试验揭示糖尿病肾病高钾血症风险的前瞻性案例研究

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-05-09 DOI: 10.1016/j.dmpk.2024.101019

Ryuta Saito, Tomohisa Nakada

{"title":"Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials","authors":"Ryuta Saito, Tomohisa Nakada","doi":"10.1016/j.dmpk.2024.101019","DOIUrl":"10.1016/j.dmpk.2024.101019","url":null,"abstract":"<div><p>The quantitative systems pharmacology (QSP) approach is widely applied to address various essential questions in drug discovery and development, such as identification of the mechanism of action of a therapeutic agent, patient stratification, and the mechanistic understanding of the progression of disease. In this review article, we show the current landscape of the application of QSP modeling using a survey of QSP publications over 10 years from 2013 to 2022. We also present a use case for the risk assessment of hyperkalemia in patients with diabetic nephropathy treated with mineralocorticoid receptor antagonists (MRAs, renin-angiotensin-aldosterone system inhibitors), as a prospective simulation of late clinical development. A QSP model for generating virtual patients with diabetic nephropathy was used to quantitatively assess that the nonsteroidal MRAs, finerenone and apararenone, have a lower risk of hyperkalemia than the steroidal MRA, eplerenone. Prospective simulation studies using a QSP model are useful to prioritize pharmaceutical candidates in clinical development and validate mechanism-based pharmacological concepts related to the risk-benefit, before conducting large-scale clinical trials.</p></div>","PeriodicalId":11298,"journal":{"name":"Drug Metabolism and Pharmacokinetics","volume":"56 ","pages":"Article 101019"},"PeriodicalIF":2.1,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1347436724000259/pdfft?md5=a676c8daea72b0c1bd3724cfc4492743&pid=1-s2.0-S1347436724000259-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141023270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical QSP application from the preclinical phase to enhance the probability of clinical success: Insights from case studies in oncology 从临床前阶段开始实际应用 QSP，提高临床成功的概率：肿瘤学案例研究的启示

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-05-09 DOI: 10.1016/j.dmpk.2024.101020

Masayo Oishi , Hiroyuki Sayama , Kota Toshimoto , Takeshi Nakayama , Yasuhisa Nagasaka

{"title":"Practical QSP application from the preclinical phase to enhance the probability of clinical success: Insights from case studies in oncology","authors":"Masayo Oishi , Hiroyuki Sayama , Kota Toshimoto , Takeshi Nakayama , Yasuhisa Nagasaka","doi":"10.1016/j.dmpk.2024.101020","DOIUrl":"10.1016/j.dmpk.2024.101020","url":null,"abstract":"<div><p>Quantitative Systems Pharmacology (QSP) has emerged as a promising modeling and simulation (M&S) approach in drug development, with potential to improve clinical success rates. While conventional M&S has significantly contributed to quantitative understanding in late preclinical and clinical phases, it falls short in explaining unexpected phenomena and testing hypotheses in the early research phase. QSP presents a solution to these limitations. To harness the full potential of QSP in early preclinical stages, preclinical modelers who are familiar with conventional M&S need to update their understanding of the differences between conventional M&S and QSP. This review focuses on QSP applications during the preclinical stage, citing case examples and sharing our experiences in oncology. We emphasize the critical role of QSP in increasing the probability of success for clinical proof of concept (PoC) when applied from the early preclinical stage. Enhancing the quality of both hypotheses and QSP models from early preclinical stage is of critical importance. Once a QSP model achieves credibility, it facilitates predictions of clinical responses and potential biomarkers. We propose that sequential QSP applications from preclinical stages can improve success rates of clinical PoC, and emphasize the importance of refining both hypotheses and QSP models throughout the process.</p></div>","PeriodicalId":11298,"journal":{"name":"Drug Metabolism and Pharmacokinetics","volume":"56 ","pages":"Article 101020"},"PeriodicalIF":2.1,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141047222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanistic pharmacokinetics & pharmacodynamics of GaINAc-siRNA GaINAc-siRNA 的机制药代动力学和药效学

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-04-01 DOI: 10.1016/j.dmpk.2023.100568

Vivaswath Ayyar

引用次数: 0

Hepatocyte formation, reactivity, and stability differences of acyl glucuronide and acyl coenzyme a conjugates 酰基葡萄糖醛酸和酰基辅酶 a 结合体在肝细胞中的形成、反应性和稳定性差异

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-04-01 DOI: 10.1016/j.dmpk.2023.100825

Carley J.S. Heck, Raman Sharma, Gregory S. Walker, Matthew A. Cerny

引用次数: 0

Practical use of mechanistic modeling to discern real word complex drug interactions 实际使用机理建模来辨别真实的复杂药物相互作用